Nitrous oxide targets brain circuits involved in mood

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial will enroll about 25 adults with treatment-resistant major depression and about 25 non-depressed healthy volunteers who are right-handed and aged 18–65. Each participant will be exposed to nitrous oxide and a placebo gas while undergoing functional connectivity MRI to compare effects on affective brain circuits. Depressed participants must have HDRS ≥17 and documented failure of ≥3–4 adequate antidepressant trials; controls must have HDRS ≤7 and no history of depression. The goal is to link nitrous oxide’s clinical effects to specific changes in brain network connectivity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults 18-65 years of age
* Right-handed
* Controls: Not meet The Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD) by scoring ≤7 on the Hamilton Depression Rating Scale (HDRS), 17-item; Treatment-Resistant Major Depression (TRMD) patients: Must meet a ≥17 score on the HDRS.
* Controls: Must not have any history of depression as determined by reported history and medical record review; TRMD: Documented (chart review) failure to respond to ≥3-4 adequate dose/duration antidepressant treatments; ≥1 in the current depressive episode.
* Good command of the English language

Exclusion Criteria:

* Meets criteria for any DSM-IV Axis I diagnosis as documented in medical records and as determined by structured clinical interview (except MDD for the TRMD group)
* Known primary neurological disorders or medical disorders including dementia, stroke, encephalopathy Parkinson's Disease, brain tumors, multiple sclerosis, seizure disorder, severe cardiac or pulmonary disease
* Any central nervous system active medication as determined by study investigator
* Any known disease affecting drug metabolism and excretion (e.g. renal or liver disease) as determined by study investigator
* Left-handedness
* Not eligible for MRI scans (e.g. history of claustrophobia/implanted metal as per MRI Screening Tool)
* Current use of psychotropic medications, antidepressants, or prescription or non-prescription drugs/herbals intended to treat depression or anxiety (control group only)
* Any recent (within past 12 months) history of substance dependence or abuse, determined by reported history or urine drug screen
* Ability to become pregnant and not using effective contraception
* Contraindication against the use of nitrous oxide:

  1. Pneumothorax
  2. Bowel obstruction
  3. Middle ear occlusion
  4. Elevated intracranial pressure
  5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12
  6. Pregnant patients
  7. Breastfeeding women
* Inability to provide informed consent
* Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic).

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Charles R Conway, MD — Washington University School of Medicine
• Study coordinator: Britt Gott, MS
• Email: gottb@wustl.edu
• Phone: 314-362-2463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new drug for treatment-resistant depression

  This study is testing a new drug called HNK to see if it can help people with treatment-resistant depression feel better when other medications haven't worked.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06511908

• SAINT therapy for memory issues in older adults with treatment-resistant depression

  This study tests whether SAINT®, a personalized, accelerated TMS treatment, can safely improve memory and mood in adults 65 and older with treatment-resistant depression and memory concerns.

  Recruiting BrainHealth Solutions, Inc. · Costa Mesa, California · NCT07876908

• Brenipatide added to standard care for adults with major depressive disorder

  This study tests whether brenipatide, given alongside standard care, can help delay the return of depressive symptoms in adults with major depressive disorder.

  Recruiting at 47 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 169 other locations · NCT07775300

• One-Day cTBS Over the Precuneus and iTBS Over the Left PFC for Treatment-Resistant Depression

  This study tests whether a one-day accelerated TMS session targeting the precuneus or the left dorsolateral prefrontal cortex can reduce depressive symptoms in adults with treatment-resistant depression, compared with sham stimulation.

  Recruiting Mclean Hospital · Belmont, Massachusetts · NCT07758010

• Esketamine nasal spray vs placebo for adults with treatment-resistant depression

  In adults who have not responded to at least two antidepressants, one of two doses of esketamine nasal spray is tested against placebo to see if it can help reduce depressive symptoms.

  Recruiting at 39 sites Phase 3 Janssen Research & Development, LLC · Redlands, California and 38 other locations · NCT07716098

• Student Precarity and Psychiatry: How Financial Struggles Relate to Depression and Loneliness

  This observational study looks at whether financial hardship and social isolation are linked to depression, suicidal thoughts, and loneliness among French university students.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, IDF · NCT07618208

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.